Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 02 2020
Historique:
received: 02 07 2019
revised: 15 07 2019
accepted: 07 08 2019
pubmed: 11 9 2019
medline: 15 5 2021
entrez: 11 9 2019
Statut: ppublish

Résumé

To describe the time trends of in-hospital and out-of-hospital bleeding parallel to the development of new treatments and ischaemic outcomes over the last 20 years in a nationwide myocardial infarction (MI) population. Patients with acute MI (n = 371 431) enrolled in the SWEDEHEART registry from 1995 until May 2018 were selected and evaluated for in-hospital bleeding and out-of-hospital bleeding events at 1 year. In-hospital bleeding increased from 0.5% to a peak at 2% 2005/2006 and thereafter slightly decreased to a new plateau around 1.3% by the end of the study period. Out-of-hospital bleeding increased in a stepwise fashion from 2.5% to 3.5 % in the middle of the study period and to 4.8% at the end of the study period. The increase in both in-hospital and out-of-hospital bleeding was parallel to increasing use of invasive strategy and adjunctive antithrombotic treatment, dual antiplatelet therapy (DAPT), and potent DAPT, while the decrease in in-hospital bleeding from 2007 to 2010 was parallel to implementation of bleeding avoidance strategies. In-hospital re-infarction decreased from 2.8% to 0.6% and out-of-hospital MI decreased from 12.6% to 7.1%. The composite out-of-hospital MI, cardiovascular death, and stroke decreased in a similar fashion from 18.4% to 9.1%. During the last 20 years, the introduction of invasive and more intense antithrombotic treatment has been associated with an increase in bleeding events but concomitant there has been a substantial greater reduction of ischaemic events including improved survival.

Identifiants

pubmed: 31504404
pii: 5554428
doi: 10.1093/eurheartj/ehz593
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

833-843

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Moa Simonsson (M)

Department of Clinical Sciences, Danderyds Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Lars Wallentin (L)

Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Joakim Alfredsson (J)

Department of Cardiology, Linkoping University Hospital, Linkoping, Sweden.

David Erlinge (D)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Karin Hellström Ängerud (K)

Department of Cardiology, Heart Centre, Umea University, Umea, Sweden.
Department of Nursing, Umea University, Umea, Sweden.

Robin Hofmann (R)

Division of Cardiology, Department of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset, Stockholm, Sweden.

Thomas Kellerth (T)

Department of Cardiology, Orebro University Hospital, Orebro, Sweden.

Lars Lindhagen (L)

Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Annica Ravn-Fischer (A)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden.

Karolina Szummer (K)

Department of Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden.

Peter Ueda (P)

Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

Troels Yndigegn (T)

Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.

Tomas Jernberg (T)

Department of Clinical Sciences, Danderyds Hospital, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH